STAT

NOVEMBER 26, 2023

LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with the chronic lung disease COPD, its developers said Monday, results that could propel the blockbuster medicine into a massive new market. Dupixent, which is jointly developed by Sanofi and Regeneron Pharmaceuticals, has already racked up approvals for several indications, including asthma, atopic dermatitis, and eosinophilic esophagitis.

Drug Development 330

Drug Development 330

The Guardian - Pharmaceutical Industry

NOVEMBER 26, 2023

Patients’ group says reactions to metamizole can cause sepsis and organ failure – and British and Irish people are at higher risk A patients group representing several British victims has launched legal action against the Spanish government over claims it failed to safeguard people against the potentially fatal side effects of one of the country’s most popular painkillers, involved in a series of serious illnesses and deaths.

134

134

ID Stewardship

NOVEMBER 26, 2023

In this article 3 clinical pharmacists provide insights, pulling from their advanced experience with beta-lactam therapeutic drug monitoring (TDM). Photo pending Authored By : Kathryn DeSear, PharmD; Barbara Santevecchi, PharmD; Veena Venugopalan, PharmD; Lisa Vuong PharmD Article Posted 28 November 2023 Beta-lactam antibiotics are time-dependent antibiotics, which means that by increasing the time the free drug concentration remains above the minimum inhibitory concentration (% f T>MIC) of

Nursing Homes 94

Nursing Homes Hospitals Dosage 94

Express Pharma

NOVEMBER 26, 2023

This study was conducted in Europe and India to examine the effects of giving patients injectable 12 mg versus 6 mg of dexamethasone every day for a maximum of 10 days There may be important regional differences in the response to higher doses of steroids (dexamethasone) for patients with severe COVID-19, according to a recent sub-study of the COVID-STEROID 2 trial.

Adverse Reactions 105

Adverse Reactions Diabetes Hospitals 105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

Drug Patent Watch

NOVEMBER 26, 2023

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Lithuania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

Pharmacy Joe

NOVEMBER 26, 2023

In this episode, I’ll discuss 5 steps an ED or ICU pharmacist can take to prevent awareness with paralysis. Episode 873: 5 Steps an ED or ICU pharmacist can take to prevent awareness with paralysis Subscribe on iTunes , Android , or Stitcher Awareness with paralysis occurs when a patient receives a paralytic for rapid sequence intubation but does not receive ongoing sedation before the induction agent wears off.

Hospitals 52

Hospitals Inpatient Labelling 52

Pharmacy Joe

NOVEMBER 26, 2023

In this episode, I’ll discuss 5 steps an ED or ICU pharmacist can take to prevent awareness with paralysis. Episode 873: 5 Steps an ED or ICU pharmacist can take to prevent awareness with paralysis Subscribe on iTunes , Android , or Stitcher Awareness with paralysis occurs when a patient receives a paralytic for rapid sequence intubation but does not receive ongoing sedation before the induction agent wears off.

Hospitals 52

Hospitals Inpatient Labelling 52